MICHAEL A DAVIES to Mice
This is a "connection" page, showing publications MICHAEL A DAVIES has written about Mice.
Connection Strength
0.188
-
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
Score: 0.012
-
Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res. 2002 Jun; 8(6):1904-14.
Score: 0.012
-
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.
Score: 0.012
-
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
Score: 0.011
-
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.
Score: 0.011
-
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
Score: 0.011
-
Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathol. 2021 02; 141(2):303-321.
Score: 0.011
-
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunol Res. 2020 11; 8(11):1365-1380.
Score: 0.010
-
Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo. Cells. 2019 11 21; 8(12).
Score: 0.010
-
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3K? Inhibition in PTEN Loss Melanoma. Clin Cancer Res. 2019 11 01; 25(21):6406-6416.
Score: 0.010
-
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019 05; 9(5):628-645.
Score: 0.009
-
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab. 2018 May 01; 27(5):977-987.e4.
Score: 0.009
-
A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.
Score: 0.009
-
Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Res. 2017 12; 27(6):545-557.
Score: 0.008
-
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
Score: 0.007
-
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest. 2014 Mar; 124(3):1406-17.
Score: 0.007
-
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013 Feb 01; 19(3):657-67.
Score: 0.006
-
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403.
Score: 0.006
-
The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer. 2012 Jul 01; 131(1):8-17.
Score: 0.006
-
Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer. 2010 Jun 09; 9:140.
Score: 0.005
-
Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010 Mar 15; 16(6):1834-44.
Score: 0.005
-
Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene. 2002 Apr 04; 21(15):2357-64.
Score: 0.003